Essity B 276.7 (+2.7 SEK) on 04-Feb-2023 17:29
Select region

Global Site

USA USA Russia Russia Germany Germany Mexico Mexico Netherlands Netherlands France France Sweden Sweden Italy Italy Spain Spain

Did you mean

    Advanced search

    Quick results

    View all results

    These might help

    Corporate press releases

    Corporate News

    Investor Relations Calendar

    Essity logo
    Brands

    Company

    Essity at a Glance
    Purpose and Vision Our Beliefs Our History
    Business Areas
    Health & Medical Consumer Goods Professional Hygiene Market and Trends Market Positions E-Commerce
    Breaking Barriers to Well-being
    Stories Partnerships Insights Events Articles
    Diversity, Equity and Inclusion
    Strategy
    Our Business Model Our Strategic Priorities
    Organization and Management
    Board of Directors CEO and EVP Business and Global Units Management Group Functions
    Corporate Governance
    Articles of Association General Meeting Nomination Committee Auditors Board and Committee Work Remuneration to the Board of Directors Remuneration Policy Public Policies Sustainability Governance
    Risk Management
    Essity in the World

    Brands

    Sustainability

    What We Do
    How We Do It
    Responsible Sourcing Resource-efficient Production Responsible Business Responsible Marketing
    Why We Do It
    Sustainable Development Goals Science Based Targets
    Our Journey to Net zero
    Key Action Areas Climate targets
    Role in Society
    Partnerships and Collaborations Essity in the Spotlight Ways of Working Trade Associations and Policy Organizations Public Policy Development Positions Advancing the Knowledge
    Human Rights
    Community Relations
    Reporting and Data
    Annual and Sustainablity Report Sustainability in Brief Essity Non-financial Reporting System Environmental Data Certification
    Recognitions and Ratings
    Contact Us

    Innovation

    Products and Solutions
    Digitalization
    Essity Ventures
    Latest Innovations

    Careers

    Job Opportunities
    Work at Essity
    Commitment to Our Employees Diversity, Equity and Inclusion Learning and Development Why Choose Essity?
    Students and Graduates
    Graduates Students Internships Apprenticeships
    Life at Essity
    Women in Technology Career Stories
    Alumni Network
    Connect with Us
    Career Events Listen to us
    Total Rewards

    Investors

    Essity as an Investment
    Targets and Outcomes
    Essity Share
    Data per Share Ownership Dividend List of Analysts Trade Information Share Conversion Share Capital Development Indexes
    Financials
    Reports
    Interim Reports Annual Reports Prospectus
    Presentations and Webcasts
    Business Area Web Presentations
    Capital Markets Day 2021
    Investor Day 2019
    Debt Financing
    Debt Programmes Credit Rating Funding Sources Key Debt Ratios
    Essity Data
    Acquisitions and Divestments
    Investor Relations Calendar
    Investor Relations Contacts
    Subscribe

    Media

    Press Releases
    News Features
    Images & Video
    Subscribe
    Media Contact
    Local Media Contacts
    Essity in Social Media
    Home
    Media
    Press releases
    2021
    Media
    Press Releases News Features Images & Video Subscribe Media Contact Essity in Social Media

    April 06, 2021

    Essity acquires distribution rights to Sorbact in Australia and New Zealand

    The leading global hygiene and health company Essity is acquiring the distribution rights to the wound care technology Sorbact® in Australia and New Zealand from the Australian company Bayport Brands. In 2020, sales of Sorbact® in the region amounted to AUD 1.7m (approximately SEK 11m). 

    “This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we – in addition to our successful Medical Solutions operations – are also in the final phase of the acquisition of Asaleo Care,” says Magnus Groth, President and CEO of Essity.

    Sorbact® is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75% of Abigo Medical in February 2020. 

    Sorbact® is used in wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact® does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment. 

    Essity acquires distribution rights to Sorbact in Australia and New Zealand
    Back to press releases

    Share this

    Essity logo
    Company Careers Brands Breaking Barriers Contact Us
    Privacy Policy Cookies Terms and Conditions

    Tel +46 8-788 51 00

    © Essity Aktiebolag (publ). Box 200, SE-101 23, Stockholm, Sweden